The Hunger Arc, Three Years Later.

The Pitch Deck Playbook  ·  Post 3 of 6

Every great investor deck follows the same underlying structure. I call it the Hunger Arc. It’s the framework I use for every biotech pitch deck I design, and once you see it, you’ll never build a deck without it.

I am a formally trained pâtissier. I went to pastry school. I can temper chocolate, laminate croissant dough, and build a croquembouche that doesn’t collapse. So when I tell you that a pitch deck should be structured like a coursed meal, I’m not reaching for a cute metaphor. I mean it literally.

A great meal doesn’t just feed you. It takes you somewhere. Each course is calibrated to prepare you for the next. The flavours build. The textures shift. By the time dessert arrives, you’re not just full. You’re satisfied in a way that a single plate, no matter how good, could never achieve.

A great biotech pitch deck does exactly the same thing. And the framework that makes it work is what I call the Hunger Arc.

The five courses

1. The amuse-bouche: problem

This is what we covered in Post 2. A small, intense burst that wakes up the palate and sets the tone.

In a biotech deck, this is the disease burden. The unmet need. The patients who are suffering and the gap in the standard of care. It should be visceral, not clinical. A single statistic in large type. A sentence that makes the room go quiet.

You’re not explaining your science yet. You’re making the investor feel why it matters. If they don’t feel the problem, nothing that follows will land.

One or two slides. No more.

2. The appetizer: solution

Now that the room is hungry, you give them the first real taste. This is your approach: what you’re building and why it’s different from everything else that’s been tried.

For a biotech company, this is where you introduce your mechanism of action, your therapeutic approach, your platform. But here’s the key: keep it accessible. You’re not defending a thesis. You’re giving a non-specialist enough understanding to feel confident that the science is real and the approach is sound.

The temptation is to go deep. Resist it. The appetizer is meant to intrigue, not to fill. If you overwhelm the investor with pathway diagrams and receptor binding data on slide four, they’ll be too full to appreciate the main course.

Two to three slides. Clean. Visual. One concept per slide.

The appetizer is meant to intrigue, not to fill.

3. The main course: traction

This is the centrepiece of the meal. The most substantial course. The one the investor came for.

In biotech, traction looks different depending on your stage. Preclinical companies show in vivo data, IP filings, key partnerships. Clinical-stage companies show trial results, enrollment numbers, regulatory milestones. Late-stage companies show the path to approval and the commercial strategy.

Whatever your stage, the main course must prove that your science isn’t just a good idea on paper. This is the data, the pipeline, the milestones that demonstrate real progress. Present it clearly, let the numbers breathe, and don’t bury the signal in noise.

This is also where most biotech decks go wrong. Founders try to serve four main courses at once: every indication, every trial, every partnership, every data readout, all crammed onto three dense slides. That’s not a main course. That’s a buffet. And buffets aren’t memorable.

Pick the strongest data. Present it with confidence. Save the rest for the appendix or the Q&A.

Three to five slides. The most room you’ll give any section.

4. The cheese course: team and plan

After the main course, the pace changes. The cheese course is quieter. More contemplative. It’s where the investor stops evaluating the science and starts evaluating the people.

This is your team slide. Your advisors. Your board. The people who make an investor believe that this particular group can execute on this particular opportunity. In biotech, credibility is everything. A CSO who ran a Phase 3 program. An advisor who sits on the FDA advisory committee. A CEO who’s done this before.

This is also where your use of proceeds and milestones live. How will you deploy the capital? What’s the timeline to the next inflection point?

The cheese course is not flashy. It’s reassuring. It says: we know what we’re doing, we have a plan, and here’s how your money gets us to the next stage.

Two to three slides.

5. The dessert: the ask

Dessert is small, sweet, and deliberate. It’s the last thing you taste, and it’s what you remember.

Your ask slide should be exactly this: how much you’re raising, what the terms are, and what the next steps look like. Clear, specific, confident. No hedging.

This is the moment the entire meal has been building toward. If you’ve structured the Hunger Arc correctly, the investor doesn’t feel like they’re being sold to. They feel like this is the natural conclusion. Of course you need capital. Every previous slide has built the case.

One slide. Maybe two if you need a timeline alongside the raise.

Skip a course or rearrange the order and the whole meal falls apart. Serve dessert first and nobody’s hungry for the rest.

Why the sequence matters

You could put all five courses on the table at once. Technically, all the same food would be there. But the experience would be completely different.

I see this constantly in biotech decks. Founders who lead with the ask. Founders who open with the team slide because they’re proud of their advisory board. Founders who jump straight to the pipeline before the investor understands why the disease matters.

Each course exists to make the next one land harder. The problem creates hunger. The solution gives the first taste. The traction proves this is real. The team proves it’s executable. And the ask is the natural conclusion.

Plating it

In the kitchen, plating is the difference between food and an experience. It’s not what you serve. It’s how you serve it.

The same principle applies to your deck. The Hunger Arc gives you the structure. But how you plate each course matters just as much. Typography, colour, space, pacing. A data slide with twelve bullet points isn’t plated. It’s slopped onto the plate. A data slide with one clear chart and two supporting numbers? That’s plated.

Post 1 in this series covers the five most common plating mistakes. If you haven’t read it yet, start there.

Every biotech pitch deck I design follows the Hunger Arc. Not because it’s a formula, but because it works. It respects the investor’s attention, it builds narrative momentum, and it makes complex science feel like a story worth investing in.

If you want help structuring your deck around this framework, that’s what the One Hour Deck Review is for.

Next up in this series: Why you actually need two decks, not one. The version you present live and the version you send as a leave-behind are fundamentally different documents. Most founders don’t realize this until it’s too late.

Book a One Hour Deck Review →

Subscribe to the Playbook →